The average gap between NHI prices and the market prices of listed medicines in Japan stood at a preliminary 5.2%…
HOME > BUSINESS
BUSINESS
- Top Five Drug Makers Report 12.8% Decline in Operating Profits with 3 Reporting Double-Digit Falls in Profits
May 17, 2012
- Final Costs to Be Confirmed by Product, Changing from Manufacturer Basis: Medipal Group
May 16, 2012
- Pivotal Focus for Biosimilars Business on Japan: Daiichi Sankyo President Nakayama
May 16, 2012
- Vedolizumab Achieved Remission in Crohn’s Disease Patients in PIII: Takeda
May 16, 2012
- Eisai to Increase the Number of Representative Corporate Officers from 2 to 5
May 16, 2012
- Ethical Drug Sales Down 0.2% in March, But Steady Despite Negative Factors: Crecon Report
May 16, 2012
- Short-Acting General Anesthetic ONO-2745/CNS 7056 Achieves Loss of Consciousness in All Patients: Ono
May 16, 2012
- Santen to Establish Presence in Market for Back-of-the-Eye Area with VEGF Trap-Eye
May 16, 2012
- Operating Profit Ratio for Pharmaceutical Wholesales at 0.32%, Improved but Still in Low Range: Top 4 Wholesalers
May 15, 2012
- Midterm Plan to Overcome Generic Versions of Actos, Setting Sights on Emerging Markets: Takeda
May 15, 2012
- Astellas to File for MDV3100 by June in Europe and US
May 15, 2012
- Takeda’s Sales Up 6.3% Driven by Nycomed Acquisition
May 15, 2012
- Otsuka HD Files for DPP-4 Inhibitor Saxagliptin
May 15, 2012
- Daiichi Sankyo: Net Profits Down 85% Due to Allowance for Potential Losses Related to Quality Problems Caused by Ranbaxy
May 15, 2012
- Otsuka HD: Pharma Sales, Profits Up; Sales of Abilify Break 400 Billion
May 15, 2012
- Eisai’s US Subsidiary Expands Exclusive Marketing Rights for Anti-Obesity Agent to 20 Countries in Americas
May 14, 2012
- Sales of Lipitor Down 6% in Fiscal Year Ended March 2012: Astellas
May 14, 2012
- Sales Force Effectiveness Japan 2012 to Be Held on July 10, 11
May 14, 2012
- Sales Up 1.6%, Vesicare Extends Global Growth: Astellas
May 14, 2012
- DSP’s Sales, Profits Down Due to Strong Yen, 1.6% Decline in Domestic Business
May 14, 2012
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…